Zacks Research Has Pessimistic Outlook of Qiagen Q3 Earnings

Key Points

• Zacks Research lowered Qiagen’s Q3 2026 EPS estimate to $0.62 from $0.63 and maintains a “Hold” rating, signaling softer near-term earnings expectations.
• Analyst sentiment remains mixed but cautious: Qiagen has an average “Hold” rating and a $43.93 price target, despite JPMorgan’s $50 target and “Overweight” rating.
• Qiagen recently exceeded quarterly expectations, reporting $0.62 EPS versus a $0.60 consensus and revenue of $535.04 million versus $527.50 million, while institutional investors own approximately 70% of the stock.

Qiagen N.V. (NYSE:QGEN - Free Report) - Equities research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Qiagen in a report issued on Wednesday, August 26th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.62 for the quarter, down from their previous estimate of $0.63. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Qiagen's current full-year earnings is $2.43 per share. Zacks Research also issued estimates for Qiagen's Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.43 EPS, Q1 2027 earnings at $0.56 EPS, Q2 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.67 EPS, Q4 2027 earnings at $0.73 EPS, FY2027 earnings at $2.60 EPS, Q1 2028 earnings at $0.68 EPS, Q2 2028 earnings at $0.72 EPS and FY2028 earnings at $2.91 EPS.

A number of other equities analysts have also commented on QGEN. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the stock an "outperform" rating in a research report on Wednesday, April 29th. Weiss Ratings raised Qiagen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Stifel Nicolaus set a $40.00 price objective on Qiagen in a report on Friday, August 7th. Citigroup reaffirmed a "neutral" rating and set a $45.00 target price (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. upped their target price on Qiagen from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $43.93.

Qiagen Price Performance

Qiagen stock opened at $43.32 on Thursday. The stock has a market cap of $8.93 billion, a price-to-earnings ratio of 22.20, a price-to-earnings-growth ratio of 4.35 and a beta of 0.63. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The firm has a 50-day moving average of $41.11 and a two-hundred day moving average of $40.70.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to analysts' expectations of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS.

Institutional Investors Weigh In On Qiagen

Several institutional investors have recently added to or reduced their stakes in the business. Boston Partners purchased a new stake in Qiagen during the 3rd quarter valued at about $179,450,000. Norges Bank acquired a new stake in shares of Qiagen during the 4th quarter worth approximately $166,500,000. Dimensional Fund Advisors LP acquired a new stake in Qiagen during the third quarter valued at $58,079,000. Price T Rowe Associates Inc. MD increased its holdings in Qiagen by 12.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company's stock valued at $379,072,000 after buying an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in Qiagen by 9.7% in the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company's stock worth $355,614,000 after purchasing an additional 697,342 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research raised its FY2028 EPS estimate to $2.91 from $2.88 and increased forecasts for Q2 2027, Q1 2028, Q2 2028 and Q4 2027. These revisions suggest some improvement in Qiagen’s longer-term earnings outlook.
• Positive Sentiment: Two potential buyers have reportedly begun formal due diligence in Qiagen’s sales process. Although no transaction is assured, the development could support takeover speculation and provide a potential catalyst for QGEN shares. Two potential buyers begin formal due diligence in Qiagen sales process
• Neutral Sentiment: Qiagen appointed Jonathan Pratt as chief executive officer. The leadership change may influence strategy, but investors will likely need more information on his priorities and execution plans before assigning a clear valuation impact. Qiagen appoints Jonathan Pratt as CEO
• Negative Sentiment: Zacks Research made several small downward revisions, lowering its FY2026 EPS estimate to $2.43 from $2.44, FY2027 to $2.60 from $2.63, Q1 2027 to $0.56 from $0.60, Q3 2026 to $0.62 from $0.63 and Q4 2026 to $0.64 from $0.65. The cuts point to somewhat softer near-term earnings expectations.
• Negative Sentiment: Zacks maintains a “Hold” rating on QGEN. The absence of a bullish rating change may limit enthusiasm despite the modest increases to some longer-term estimates.

Qiagen Company Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source